Dr. John B. Buse, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 56
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Duke University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
NC license 9400739
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 56
- Services billed
- 248
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 151 | 62 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 76 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metformin Hcl Other prescribers in Chapel Hill, NC | 119 |
| Atorvastatin Calcium Other prescribers in Chapel Hill, NC | 112 |
| Ozempic (semaglutide) Other prescribers in Chapel Hill, NC | 92 |
| Rosuvastatin Calcium Other prescribers in Chapel Hill, NC | 87 |
| Jardiance (empagliflozin) Other prescribers in Chapel Hill, NC | 66 |
| Levothyroxine Sodium Other prescribers in Chapel Hill, NC | 65 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Chapel Hill, NC | 51 |
| Mounjaro (tirzepatide) Other prescribers in Chapel Hill, NC | 50 |
| Losartan Potassium Other prescribers in Chapel Hill, NC | 49 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Chapel Hill, NC | 41 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 52 payments worth $87,608 in total to this clinician.
| Novo Nordisk As | $25,029 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $16,616 |
| Eli Lilly and Company | $11,514 |
| Recordati_rare_diseases_inc. | $9,136 |
| Vertex Pharmaceuticals Incorporated | $7,636 |
| Amgen Inc. | $7,078 |
| Corcept Therapeutics | $6,100 |
| Novo Nordisk Inc | $4,500 |
| Consulting Fee | $53,401 |
|---|---|
| Travel and Lodging | $18,275 |
| Honoraria | $8,000 |
| Compensation for services other than consulting (speaking, faculty) | $6,823 |
| Food and Beverage | $1,109 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Oct 31, 2025 | Consulting Fee | $11,375 |
| Novo Nordisk As Sep 15, 2025 | Consulting Fee Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,375 |
| Recordati_rare_diseases_inc. May 31, 2025 | Honoraria OSILODROSTAT · ENDOCRINE AGENT | $8,000 |
| Novo Nordisk As Sep 15, 2025 | Travel and Lodging Diabetes · travel to Vienna, Austria · in-kind | $7,209 |
| Novo Nordisk As Apr 21, 2025 | Travel and Lodging Diabetes · travel to Copenhagen, Denmark · in-kind | $6,134 |
| Novo Nordisk Inc Jan 1, 2025 | Consulting FeeCompany’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $4,500 |
| Amgen Inc. May 13, 2025 | Consulting Fee | $4,470 |
| Corcept Therapeutics Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) Korlym · Endocrinology | $4,350 |
| AstraZeneca Pharmaceuticals LP Jul 22, 2025 | Consulting Fee | $4,296 |
| Vertex Pharmaceuticals Incorporated Dec 17, 2025 | Consulting Fee | $3,988 |
All 42 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Dec 17, 2025 | Consulting Fee | $3,988 |
| Vertex Pharmaceuticals Incorporated Dec 17, 2025 | Consulting Fee | $1,470 |
| Vertex Pharmaceuticals Incorporated Dec 17, 2025 | Travel and Lodging travel to CHAPEL HILL, NC · in-kind | $31.50 |
| Vertex Pharmaceuticals Incorporated Dec 17, 2025 | Travel and Lodging travel to CHAPEL HILL, NC · in-kind | $26.30 |
| Vertex Pharmaceuticals Incorporated Dec 17, 2025 | Travel and Lodging travel to CHAPEL HILL, NC · in-kind | $14.70 |
| AstraZeneca Pharmaceuticals LP Dec 15, 2025 | Consulting Fee | $1,074 |
| Corcept Therapeutics Dec 10, 2025 | Compensation for services other than consulting (speaking, faculty) Korlym · Endocrinology | $1,750 |
| Eli Lilly and Company Nov 13, 2025 | Travel and Lodging travel to LISBON, Portugal | $105 |
| Eli Lilly and Company Nov 13, 2025 | Travel and Lodging travel to LISBON, Portugal | $33.60 |
| Vertex Pharmaceuticals Incorporated Nov 7, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $406 |
| Vertex Pharmaceuticals Incorporated Nov 7, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $350 |
| Vertex Pharmaceuticals Incorporated Nov 7, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $233 |
| Vertex Pharmaceuticals Incorporated Nov 6, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $916 |
| Eli Lilly and Company Oct 31, 2025 | Consulting Fee | $11,375 |
| Amgen Inc. Oct 21, 2025 | Consulting Fee | $1,863 |
| Amgen Inc. Oct 21, 2025 | Consulting Fee | $745 |
| AstraZeneca Pharmaceuticals LP Oct 15, 2025 | Consulting Fee | $1,074 |
| AstraZeneca Pharmaceuticals LP Oct 15, 2025 | Consulting Fee | $1,000 |
| Novo Nordisk As Sep 15, 2025 | Consulting Fee Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,375 |
| Novo Nordisk As Sep 15, 2025 | Travel and Lodging Diabetes · travel to Vienna, Austria · in-kind | $7,209 |
| Novo Nordisk As Sep 15, 2025 | Travel and Lodging Diabetes · travel to Vienna, Austria · in-kind | $1,298 |
| Novo Nordisk As Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) Diabetes | $723 |
| Novo Nordisk As Sep 15, 2025 | Travel and Lodging Diabetes · travel to Vienna, Austria · in-kind | $170 |
| AstraZeneca Pharmaceuticals LP Jul 22, 2025 | Consulting Fee | $4,296 |
| AstraZeneca Pharmaceuticals LP Jul 15, 2025 | Consulting Fee | $750 |
| AstraZeneca Pharmaceuticals LP Jul 15, 2025 | Consulting Fee | $700 |
| Recordati_rare_diseases_inc. May 31, 2025 | Honoraria OSILODROSTAT · ENDOCRINE AGENT | $8,000 |
| Recordati_rare_diseases_inc. May 31, 2025 | Travel and Lodging OSILODROSTAT · ENDOCRINE AGENT · travel to CHICAGO, IL | $519 |
| Recordati_rare_diseases_inc. May 30, 2025 | Travel and Lodging OSILODROSTAT · ENDOCRINE AGENT · travel to CHICAGO, IL | $200 |
| AstraZeneca Pharmaceuticals LP May 19, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $537 |
| AstraZeneca Pharmaceuticals LP May 15, 2025 | Consulting Fee | $1,500 |
| Amgen Inc. May 13, 2025 | Consulting Fee | $4,470 |
| Novo Nordisk As Apr 21, 2025 | Travel and Lodging Diabetes · travel to Copenhagen, Denmark · in-kind | $6,134 |
| Novo Nordisk As Apr 21, 2025 | Travel and Lodging Diabetes · travel to Copenhagen, Denmark · in-kind | $343 |
| Novo Nordisk As Apr 21, 2025 | Travel and Lodging Diabetes · travel to Copenhagen, Denmark · in-kind | $286 |
| AstraZeneca Pharmaceuticals LP Apr 15, 2025 | Consulting Fee | $1,000 |
| Corcept Therapeutics Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) Korlym · Endocrinology | $4,350 |
| AstraZeneca Pharmaceuticals LP Mar 15, 2025 | Consulting Fee | $1,000 |
| AstraZeneca Pharmaceuticals LP Feb 15, 2025 | Consulting Fee | $1,611 |
| AstraZeneca Pharmaceuticals LP Feb 15, 2025 | Consulting Fee | $1,074 |
| AstraZeneca Pharmaceuticals LP Jan 15, 2025 | Consulting Fee | $1,000 |
| Novo Nordisk Inc Jan 1, 2025 | Consulting FeeCompany’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $4,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $151,701 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Novo Nordisk As - Study name not reported
Novo Nordisk As - Study name not reported
Novo Nordisk As - Study name not reported
Novo Nordisk As
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.